scholarly journals Aceclofenac–tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone

2009 ◽  
Vol 18 (12) ◽  
pp. 1836-1842 ◽  
Author(s):  
Anil Pareek ◽  
Nitin Chandurkar ◽  
A. S. Chandanwale ◽  
Ratnakar Ambade ◽  
Anil Gupta ◽  
...  
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Comparative Study ◽  
Low Back ◽  
Double Blind ◽  
Acute Low Back Pain

The efficacy and safety of a homeopathic gel in the treatment of acute low back pain: a multi-centre, randomised, double-blind comparative clinical trial

2001 ◽  
Vol 90 (01) ◽  
pp. 21-28 ◽  
Author(s):  
C Stam ◽  
MS Bonnet ◽  
RA van Haselen
Keyword(s):  
Clinical Trial ◽  
Low Back Pain ◽  
Back Pain ◽  
Controlled Clinical Trial ◽  
Low Back ◽  
Double Blind ◽  
Acute Low Back Pain ◽  
Efficacy Parameter ◽  
Industrialised Countries ◽  
Topical Medications

AbstractAcute low back pain is a very common condition in Western industrialised countries. In most cases analgesics or topical medications are prescribed at first encounter with the general practitioner (GP).The aim of this study was to investigate whether the homeopathic gel Spiroflor SRL® gel (SRL) is equally effective and better tolerated than Cremor Capsici Compositus FNA (CCC) in patients with acute low back pain.A multi-centre, randomised, double-blind, controlled clinical trial was conducted in the practices of 19 GPs in the districts of Bristol and Manchester, UK. One hundred and sixty-one subjects suffering from acute low back pain were treated for one week either with SRL or with CCC. Pain was scored on a 100 mm visual analogue scale (VAS). Main efficacy parameter VAS reduction was compared between treatments. Evaluation of safety was primarily based on the number of subjects with adverse events (AEs), withdrawals due to an AE and adverse drug reactions (ADRs).The mean difference between the VAS reduction in the SRL group and the CCC group adjusted for VAS at baseline and age was −0.6 mm (90%CI=−6.5–5.3 mm). Fewer subjects in the SRL group (11%) experienced an AE than in the CCC group (26%). The same applies to the number of subjects with an ADR (3/81=4% vs 18/74=24%) and the number of subjects withdrawn due to an ADR (0/81=0% vs 8/74=11%).In conclusion, SRL and CCC are equally effective in the treatment of acute low back pain, however, SRL has a better safety profile. Spiroflor SRL® gel is preferable to Capsicum-based products for the topical treatment of low back pain, because of the lower risk of adverse effects.

scholarly journals A COMPARATIVE STUDY ON EFFICACY AND SAFETY OF TOLPERISONE VERSUS TIZANIDINE IN PATIENTS SUFFERING FROM ACUTE LOW BACK PAIN WITH MUSCLE SPASM

2021 ◽  
pp. 153-157
Author(s):  
ABDUL FAHEEM KHAN ◽  
KHANETA PARVEEN
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Comparative Study ◽  
Clinical Symptoms ◽  
Mean Value ◽  
Muscle Spasm ◽  
Low Back ◽  
Efficacy And Safety ◽  
Acute Low Back Pain ◽  
Significant Difference

OBJECTIVES: The objectives of this study were to compare the efficacy and safety of Tolperisone tablets 50 mg three times daily versus Tizanidine 2 mg tablets thrice daily for the treatment of acute low back pain with muscle spasm. METHODS: The comparative study was carried out in 50 patients from orthopedics Dr. Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation, Vijayawada. Only those patients fulfilling the inclusion/exclusion criteria were enrolled into the study. Participants suffering from acute low back pain with muscle spasm were divided into two groups. The participants were followed up on Day-14 as final analysis. RESULTS: Subjects receiving Tolperisone showed a mean value of 16.43±1.16 in the Roland Morris low back pain and disability questionnaire both groups on day 1 and was reduced to 7.82±1.15 (51.94%) on day 7 and 2.56±1.53 (84.46%) on day 14. Similarly, the patients in the tizanidine group had mean value of 15.93±1.61 on day 1, which was reduced to 6.77±1.68 (57.64%) on day 7, and 2.88±1.92 (81.95%) on day 14, as comparable to the Tolperisone group. There was no statistically significant difference between the two groups, (p>0.05) for pain at rest, pain at night, restrictions of movement, changes in stiffness, changes in numbness, and changes in tenderness. There was a statistically significant difference between the two groups, (p<0.05) for pain on movement and kinesalgia. CONCLUSIONS: Tolperisone was found comparable in efficacy to Tizanidine in improving the clinical symptoms of changes in pain Self-assessment by the patient on different applied parameters.

scholarly journals Double-blind, randomized, double-dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain

2016 ◽  
pp. 1987 ◽  
Author(s):  
Pérola Grinberg Plaper ◽  
Morton Scheinberg ◽  
Christina Ecclissato ◽  
Monalisa Oliveira ◽  
Roberto Amazonas
Keyword(s):  
Clinical Trial ◽  
Low Back Pain ◽  
Back Pain ◽  
Low Back ◽  
Double Blind ◽  
Acute Low Back Pain

A Multicentre Placebo-Controlled Study in General Practice to Evaluate the Efficacy and Safety of Tizanidine in Acute Low-Back Pain

1988 ◽  
Vol 16 (2) ◽  
pp. 75-82 ◽  
Author(s):  
H. Berry ◽  
D. R. Hutchinson
Keyword(s):  
General Practice ◽  
Low Back Pain ◽  
Back Pain ◽  
Bed Rest ◽  
Controlled Study ◽  
Low Back ◽  
Double Blind ◽  
Recent Onset ◽  
Acute Low Back Pain ◽  
Pain At Rest

Patients (112) with acute low-back pain of recent onset were recruited to this double-blind, randomized, placebo-controlled parallel group study in general practice to evaluate the efficacy and tolerability of the muscle relaxant, tizanidine. They were treated for 7 days with tizanidine (4 mg three times daily) or matching placebo. Aspirin tablets (300 mg) were taken as required as ‘rescue’ medication. Symptoms were assessed by the patient and doctor before treatment, and after 3 and 7 days. Patients recorded pain and aspirin consumption in a daily diary. Both treatments were effective. In patients who had taken no medication prior to entry, aspirin consumption was almost halved in the first 3 days of taking tizanidine compared with placebo ( P = 0.037). Results for pain at rest, pain at night, restriction of movement and pain on movement suggest that tizanidine may give greater improvement, earlier. No serious drug-related adverse events or abnormal biochemistry or haematology were observed in either group. Drowsiness occurred in 22% of patients taking tizanidine although, in patients with severe acute low-back pain, sedation, analgesia and bed rest might be beneficial and desired. Considerably more patients given aspirin/placebo had gastro-intestinal side-effects ( P = 0.018). In conclusion, tizanidine may reduce the need for analgesics and be useful in the treatment of acute low-back pain.

scholarly journals Clinical Comparative Study: Efficacy and Tolerability of Tolperisone and Thiocolchicoside in Acute Low Back Pain and Spinal Muscle Spasticity

2012 ◽  
Vol 6 (2) ◽  
pp. 115 ◽  
Author(s):  
Rajeev Rao ◽  
Atul Panghate ◽  
Ajay Chandanwale ◽  
Indrajeet Sardar ◽  
Mriganka Ghosh ◽  
...  
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Comparative Study ◽  
Low Back ◽  
Muscle Spasticity ◽  
Acute Low Back Pain
Sign in / Sign up

Export Citation Format

Share Document